Publicly accessible evidence of health related quality of life benefits associated with cancer drugs approved by the European Medicines Agency between 2009 and 2015

Background Health-related quality of life (HRQoL) is one of the most important patient-relevant study endpoints for the direct measurement of the benefit of cancer drugs. Therefore, our aim was to detect cancer indications with no published information on HRQoL at the time of European Medicines Agency (EMA) approval and monitor any reported HRQoL evidence updates after at least three years follow-up. Methods We included all cancer indications that were approved by the EMA between January 2009 and October 2015. Our main sources of information were the EMA website, clinicaltrials. gov and a systematic literature s…